Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119581 · ClinicalTrials.gov registry record · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,264
- Enrollment target
- 20
- Study locations
NCT06119581 is a Phase 3 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,264 participants, above the 314-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (303% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06119581, a Phase 3 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Placebo
- DRUG Cisplatin
- DRUG LY3537982
Study Locations (20)
Florida
- Millennium Oncology Research Clinic - Hollywood
- University of Florida - Jacksonville - Jacksonville
- Miami Cancer Institute at Baptist Health, Inc. - Miami
- Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala - Ocala
- Comprehensive Hematology Oncology - St. Petersburg
California
- Cedars-Sinai Medical Center - Los Angeles
- Mercy Cancer Center - Merced
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
- BASS Cancer Center - Walnut Creek
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Banner University Medical Center Phoenix - Phoenix
- The University of Arizona Cancer Center - North Campus - Tucson
Georgia
- University Cancer & Blood Center, LLC - Athens
- Emory University School of Medicine- Grady Campus - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Alabama
- Clearview Cancer Institute - Huntsville
Arkansas
- Highlands Oncology Group - Springdale
Colorado
- USO - Rocky Mountain Cancer Centers - Lone Tree
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,264 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06119581
The ClinicalTrials.gov registry entry for NCT06119581 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,264 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 314-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (303% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06119581 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06119581 about?
NCT06119581 is a clinical study titled "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer". The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including fo...
What is the current status of trial NCT06119581?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,264 participants. The study started on 2023-12-21. Estimated completion is 2031-01.
What conditions does trial NCT06119581 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Neoplasm Metastasis.
What interventions are being tested in trial NCT06119581?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Placebo (DRUG), Cisplatin (DRUG), LY3537982 (DRUG).
Who is sponsoring clinical trial NCT06119581?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119581 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.